Spruce Biosciences SPRB

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$17.54 (-11.84%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Spruce Biosciences (SPRB) Business Model and Operations Summary
    Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

    Key Insights

    Spruce Biosciences (SPRB) Stock Information & Key Business Metrics

    • Latest Closing Price

      $129.54

    • Market Cap

      $12.10 Million

    • Average Daily Volume

      371,603 Shares

    • 52-Week Range

      $0.26-$0.87

    • Price-Earnings Ratio

      -0.06

    • Total Outstanding Shares

      563,042 Shares

    • CEO

      Dr. Javier Szwarcberg M.D., M.P.H.

    • Total Employees

      20

    • Current Dividend

      No dividend

    • IPO Date

      October 9, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Headquarters

      611 Gateway Boulevard, Suite 740, South San Francisco, CA, 94080

    Financial Highlights

    Spruce Biosciences (SPRB) Key Financial Metrics

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Cash Flow Statement

    Income Statement

    Balance Sheet

    Historical Stock Splits

    If you bought 75 shares of SPRB before August 7, 2025, you'd have 1 share today

    Historical Dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about SPRB from trusted financial sources

    Related Companies

    Publicly traded companies similar to Spruce Biosciences (SPRB)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.

    Play

    The Daily FinanchleSPY Prediction

    Explore

    Live Market OverviewS&P 500 SPYNasdaq 100 QQQRussell 2000 IWMUnusual Options Activity

    Research

    News ArticlesEarnings CalendarIPO Calendar & DirectoryAll Tickers

    Financhle

    Login / Sign UpPro SubscriptionAbout UsCareersTerms & ConditionsPrivacy & Cookies Info

    ⓒ 2025 Financhle LLC. All Rights Reserved.